Premium
The evaluation of immune responses to hepatitis B vaccination in diabetic and non‐diabetic haemodialysis patients and the use of tetanus toxoid
Author(s) -
OCAK SABAHATTIN,
ESKIOCAK ALI FUAT
Publication year - 2008
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2008.00936.x
Subject(s) - medicine , toxoid , tetanus , vaccination , diabetes mellitus , booster dose , immunology , antibody , immune system , hepatitis b vaccine , hepatitis b , gastroenterology , immunization , hbsag , hepatitis b virus , endocrinology , virus
SUMMARY: Aim: The aim of this study was to investigate whether haemodialysis (HD) patients suffering from diabetes mellitus could be considered at risk for the development of the protective antibodies to hepatitis B (HB) vaccination and, to evaluate the effectiveness of tetanus toxoid (TT) administrated 2 days before HB vaccination. Methods: Forty‐nine HD patients were divided into two groups: group A (19 diabetic patients) and group B (30 non‐diabetic patients). A dose of 40 μg recombinant HB vaccine was injected intramuscularly to the patients at 0, 1, 2 and 6 months. Results: After the completion of the course, the patients in group A were found to have a lower protective antibody rates than the patients in group B (57.8% vs 70%) ( P > 0.05). After the administration of additional booster doses during 12 months, the protective antibody to hepatitis B surface antigen (HBsAb) levels were detected in 78.9% and 96.6% of the patients in group A and group B, respectively ( P > 0.05). The patients not having protective HBsAb levels were administered TT and HB vaccines, and after course, all of them have produced protective HBsAb levels. Conclusion: The present study showed that diabetic patients on HD may carry a greater risk of not seroconverting than non‐diabetic ones for antibody response to HB vaccination. The use of TT 2 days before HB vaccination may be a useful and effective method of enhancing the immune response to HB vaccination, especially in the patients with diabetes mellitus on HD.